Quadrant Capital Group’s Nutex Health NUTX Stock Holding History

Quadrant Capital Group’s Portfolio NUTX Stock Details NUTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$191	–	2123
2026 Q1	$191	Buy	+2	New	+$245	﹤0.01%	2668

Other funds holding NUTX

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Winmill & Co Walpole, New Hampshire $452M AUM 56.84% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Quadrant Capital Group's NUTX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Nutex Health (NUTX) in Q2 2026, closing a stake of 2 shares — an estimated $191 sold.

Quadrant Capital Group first reported a position in NUTX in Q1 2026 and held it in 1 quarter. The position peaked at $191 in Q1 2026. 154 funds tracked by Wall St. Rank hold NUTX as of Q2 2026.

Quadrant Capital Group reported no remaining Nutex Health position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 2 Nutex Health shares in Q2 2026, an estimated $191.
Quadrant Capital Group first reported a position in Nutex Health in Q1 2026 and held it in 1 quarter.
Quadrant Capital Group's Nutex Health position peaked at $191 in Q1 2026.
154 funds tracked by Wall St. Rank held Nutex Health as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.